WOBURN, Mass.--(BUSINESS WIRE)--
ArQule, Inc. (Nasdaq: ARQL) today announced that the Company will
present at the UBS Global Life Sciences Conference on Wednesday,
September 19, 2012 at 1:00 p.m. The presentation will be web cast and
may be accessed through the investor relations section of the Company's
ArQule is a biotechnology company engaged in the research and
development of next-generation, small-molecule cancer therapeutics. The
Company's targeted, broad-spectrum products and research programs are
focused on key biological processes that are central to human cancers.
ArQule's lead product candidate, in Phase 2 and Phase 3 clinical
development together with development and commercialization partner,
Daiichi Sankyo, Co. Ltd., is tivantinib, an oral, selective inhibitor of
the c-MET receptor tyrosine kinase. The Company's pipeline consists of
ARQ 621, designed to inhibit the Eg5 kinesin motor protein, and ARQ 736,
designed to inhibit the RAF kinases. ArQule's current discovery efforts,
which are based on the ArQule Kinase Inhibitor Platform (AKIP™), are
focused on the identification of novel kinase inhibitors that are
potent, selective and do not compete with ATP (adenosine triphosphate)
for binding to the kinase.
William B. Boni, 781-994-0300
Source: ArQule, Inc.
News Provided by Acquire Media